Immunovant announces next-generation anti-FcRn IMVT-1402 with promising preclinical data

Immunovant, Inc.

IMVT-1402 showed deep IgG lowering with minimal impact on albumin and LDL in animal studies.
Plan to submit IND and initiate Phase 1 study in early 2023 with initial data expected in mid-2023.
Cash runway guidance into calendar year 2025 remains unchanged, including Phase 1 costs for IMVT-1402.
Composition of matter patent protection expected for IMVT-1402 through at least 2042.
Batoclimab programs in Myasthenia Gravis, Thyroid Eye Disease, CIDP and Graves' Disease continue at full speed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.